Ubs Group Ag Avadel Pharmaceuticals PLC Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$12.55 - $17.22 $27,986 - $38,400
2,230 Added 19.73%
13,530 $228,000
Q4 2023

Feb 09, 2024
SELL
$9.64 - $14.59 $1,291 - $1,955
-134 Reduced 1.17%
11,300 $159,000
Q3 2023

Nov 09, 2023
SELL
$10.3 - $15.99 $20,126 - $31,244
-1,954 Reduced 14.6%
11,434 $117,000
Q2 2023

Aug 11, 2023
BUY
$8.48 - $16.48 $23,040 - $44,776
2,717 Added 25.46%
13,388 $220,000
Q1 2023

May 12, 2023
BUY
$6.41 - $9.95 $49,645 - $77,062
7,745 Added 264.7%
10,671 $97,000
Q4 2022

Feb 08, 2023
SELL
$5.02 - $10.0 $45,325 - $90,290
-9,029 Reduced 75.52%
2,926 $20,000
Q3 2022

Nov 10, 2022
BUY
$2.57 - $7.31 $23,055 - $65,578
8,971 Added 300.64%
11,955 $60,000
Q2 2022

Aug 10, 2022
SELL
$1.07 - $6.95 $345 - $2,244
-323 Reduced 9.77%
2,984 $7,000
Q1 2022

May 16, 2022
SELL
$5.46 - $8.29 $27,032 - $41,043
-4,951 Reduced 59.95%
3,307 $23,000
Q4 2021

Feb 14, 2022
SELL
$7.34 - $11.18 $31,143 - $47,436
-4,243 Reduced 33.94%
8,258 $67,000
Q3 2021

Nov 15, 2021
SELL
$6.49 - $9.91 $6,379 - $9,741
-983 Reduced 7.29%
12,501 $122,000
Q2 2021

Aug 13, 2021
BUY
$6.73 - $9.05 $44,525 - $59,874
6,616 Added 96.33%
13,484 $91,000
Q1 2021

May 12, 2021
BUY
$6.61 - $10.07 $14,277 - $21,751
2,160 Added 45.88%
6,868 $63,000
Q4 2020

Feb 11, 2021
BUY
$5.03 - $7.95 $3,686 - $5,827
733 Added 18.44%
4,708 $32,000
Q3 2020

Nov 12, 2020
SELL
$5.02 - $8.98 $3,609 - $6,456
-719 Reduced 15.32%
3,975 $20,000
Q2 2020

Jul 31, 2020
BUY
$7.25 - $11.75 $10,650 - $17,260
1,469 Added 45.55%
4,694 $38,000
Q1 2020

May 01, 2020
SELL
$4.06 - $10.64 $16,219 - $42,506
-3,995 Reduced 55.33%
3,225 $26,000
Q4 2019

Feb 14, 2020
BUY
$3.34 - $7.7 $9,251 - $21,329
2,770 Added 62.25%
7,220 $54,000
Q3 2019

Nov 14, 2019
BUY
$1.92 - $4.47 $4,692 - $10,924
2,444 Added 121.83%
4,450 $18,000
Q2 2019

Aug 14, 2019
BUY
$1.09 - $3.19 $2,073 - $6,067
1,902 Added 1828.85%
2,006 $6,000
Q1 2019

May 14, 2019
SELL
$1.44 - $3.29 $4,428 - $10,116
-3,075 Reduced 96.73%
104 $0
Q4 2018

Feb 14, 2019
SELL
$1.74 - $4.66 $4,938 - $13,225
-2,838 Reduced 47.17%
3,179 $8,000
Q3 2018

Nov 14, 2018
BUY
$4.08 - $7.14 $5,389 - $9,431
1,321 Added 28.13%
6,017 $26,000
Q2 2018

Aug 14, 2018
BUY
$5.89 - $7.78 $20,538 - $27,128
3,487 Added 288.42%
4,696 $29,000
Q1 2018

May 15, 2018
SELL
$6.76 - $11.7 $5,002 - $8,658
-740 Reduced 37.97%
1,209 $8,000
Q4 2017

Feb 14, 2018
BUY
$8.03 - $11.25 $15,216 - $21,318
1,895 Added 3509.26%
1,949 $16,000
Q3 2017

Nov 14, 2017
SELL
$8.35 - $10.5 $20,357 - $25,599
-2,438 Reduced 97.83%
54 $1,000
Q2 2017

Aug 14, 2017
BUY
N/A
2,362 Added 1816.92%
2,492 $28,000
Q1 2017

Nov 14, 2017
BUY
N/A
130
130 $2,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email